Opsis Therapeutics was launched in late Septber by Cellular Dynamics International (CDI), a US-based manufacturer of induced pluripotent st cell (iPSC) products.{{quote-A:R-W:450-I:2-Q: At Opsis Therapeutics, we see promise in a variety of new approaches, -WHO:Dr David Gamm, chief scientific officer of Opsis Therapeutics}}The new company’s focus is on the discovery and development of medicines to treat patients suffering from acquired and inherited retinal diseases such as age-related macular degeneration and retinitis pigmentosa.Opsis Therapeutics chief scientific officer Dr David Gamm said that while the conditions afflicted tens of millions of people worldwide, there were currently no therapeutic options available to mitigate or restore the permanent loss of vision and blindness they could cause.“At Opsis Therapeutics, we see promise in a variety of new approaches,” he stated. “For example, over the past decade, it has become feasible to generate new photoreceptors from iPSCs and transplant th into the diseased retina, with additional advances anticipated in the future.”He added that the company’s goal was to build on this progress and improve the standard of care for patients. It will also work to build up a pipeline of therapeutic candidates.
CooperVision names Muru Annamalai as APAC president
CooperVision has named Muru Annamalai as president, Asia-Pacific, stating the experienced global healthcare leader will guide growth across the region....
